Overview

Bladder cancer makes up about 4% of cancers in the US. It is the fourth most common cancer in men, but it’s less common in women. Join us for a FREE half-day, in-person event and understand the latest treatment options, diagnostic tests, imaging, and multidisciplinary treatment of non-muscle invasive bladder cancer, muscle-invasive bladder cancer, and metastatic urothelial cancer. The education will foster collaborative efforts amongst Inova physicians, APPs, nurses, and allied health professionals.

Learning Objectives

• Summarize the VIRADS system for diagnosing bladder tumors.
• Indicate the state-of-the-art treatments with intravesical therapies in non-muscle-invasive bladder cancers (NMIBC).
• Identify bladder preservation in muscle-invasive bladder cancer (MIBC).
• Determine the role of genomics and implications in diagnosis and treatment in urothelial cancers.
• Obtain updates in systemic therapy applications in muscle-invasive bladder cancer especially with adjuvant therapy and the changing landscape of metastatic urothelial cancer treatments

Target Audience

• Advanced Practice Providers
• Dietitians
• Family Medicine
• Genetic Counselors
• Internists
• Medical Oncologists
• Nurses
• Nurse Navigators
• Physicians
• Radiation Oncologists
• Radiologists
• Therapists
• Urologists
• Urologic Oncologists
• Residents, Students, and Fellows
• Other Allied Health professionals and Trainees

Accreditation

The Inova Office of Continuing Medical Education designates this live educational activity for a maximum of 3.5 AMA PRA Category 1 Credit(s) ™. Physicians should only claim credit commensurate with the extent of their participation in the activity. Physicians may claim up to 3.5 credits in Type 1 CME on the Virginia Board of Medicine Continued Competency and Assessment Form required for renewal of an active medical license in Virginia.

For more information please visit the official event page.